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Abstract
MicroRNAs play critical role in regulating gene expression. MicroRNA profile of particular cell type
bears the signature of cell type specific gene expression. Given that viral pathogens replicate by
evading host defenses, research is now focused on the miRNA-regulated genes that critically
regulate HIV-1 propagation in human host cells.
Background
Ever since the initial report [1] that C. elegans lin-4 gene
product, a 21 nucleotide non-coding RNA (ncRNA), regu-
lates the expression of lin-14 by partial complementarity
to several regions within the 3'-UTR of the target lin-14
mRNA, RNA-mediated gene silencing (RNAi) has taken
on new urgency to understand its role in regulating gene
expression in mammalian cells. A recent report in Science
[2] argues that RNAi limits the replication of HIV-1 in
human cells, and that cellular micro-RNAs (miRNAs) con-
tribute to this antiviral response. This report opens the
inquiry into exciting new area of virus-host interaction
and asks how viral infection overcomes the limitations
imposed on virus life cycle by the host miRNA-mediated
defenses.
Nearly 500 human genes are known to encode ~21 nucle-
otide miRNAs, which are initially transcribed by RNA
Polymerase II as primary (pri-miRNA) that are processed
in the nucleus by RNase type III Drosha into precursor
(pre-miRNA) and exported to the cytoplasm by exportin
5, to be secondarily processed into miRNA duplexes by
the cytoplasmic RNAse type III Dicer. The resulting
miRNA duplexes are incorporated into the RNA-Induced
Silencing Complex (RISC) where one of the miRNA
strands, the 'passenger' is degraded, while the 'guide'
miRNA is guided to the target mRNA to either degrade (in
case of perfect base complementarity) or to block transla-
tion (in case of imperfect sequence complementarity
between the miRNA 'seed' sequence and the target
mRNA). This general version of miRNA action (Figure 1)
may not be universally true in all cases; nevertheless,
examining the miRNA-targeted genes has allowed a
detailed understanding of the host response to the stress
induced by viral infection.
Triboulet et al., [2] show that reducing the Drosha or
Dicer levels in host cells allowed faster kinetics of HIV-1
production. One could quibble with the fact that siRNA-
mediated knock down of Drosha and Dicer levels in the
host cells may be considered a 'blunt tool'. The results
nevertheless argue that the intact RNAi pathway of the
host keeps virus replication in check. The question is how?
What are the miRNA mediators of host defense that HIV
needs to overcome in order to propagate? The authors
analyzed miRNA landscape in uninfected and HIV-1
infected cells and found that several miRNAs (miR-122,
miR-370, miR-373 and miR-297) are up regulated during
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miRNAs are not normally expressed in T-cells. Could
these up regulated miRNAs modulate expression of host
genes related to basal response to virus replication? This
report does not pursue the role of host genes that are tar-
geted by the miRNAs up-regulated during HIV-1 replica-
tion.
The experiments discussed by Triboulet et al, however do
emphasize the importance of the miR-17/92 cluster that is
down-regulated during HIV replication. The down-regu-
lated miRNAs include, miR-17-5p/3p, miR-18, miR-19a,
miR-2a, miR196-1 and miR-92-1. Significantly, host pro-
teins targeted by the miR-17/92 cluster include histone
acetylase, PCAF; PCAF has been shown to be an important
co-factor in Tat-transactivation and HIV-1 replication.
There are four potential targets within the PCAF 3'-UTR
for miR-17-5p and miR-2a binding which could lead to
translational inhibition of the PCAF-transcript. Over
expression of miR-17-5p or miR-2a resulted in dramatic
reduction of HIV-1 production. Importantly, the restora-
tion of PCAF protein levels, as indicated by the expression
of PCAF cDNA vectors lacking the 3'-UTR, was sufficient
to relieve the suppression of HIV-1 production imposed
by the miRNAs. One could argue that histone acetylation
is a general positive regulator of transcription; a point sup-
ported by the observation that the repressive effect of
RNAi on HIV-1 replication was also seen in latently
infected U1 cells which express a mutant Tat and are una-
ble to efficiently activate HIV-1 LTR [3].
Outlines the restriction on virus replication imposed by host cell RNAi responseFigur  1
Outlines the restriction on virus replication imposed by host cell RNAi response. Intact RNAi response, or over expression of 
miR-17/miR-2a severely restricts HIV-1 replication. Host proteins targeted by miRNAs include PCAF, a HIV-1 Tat-cofactor, its 
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of specific gene expression pattern of that cell type [4]. The
repertoire of expressed miRNAs varies from one cell type
to another. Although the basic steps in miRNA biogenesis
are known, it is less clear how miRNA expression is regu-
lated in different cell types. Importantly, it is largely
unknown how virus replication influences the abundance
and the distribution of miRNAs within the host cell.
Given the importance of miRNAs as critical effectors that
modulate specific protein levels, changes in miRNA land-
scape during virus replication is a promising approach to
understand molecular regulation of host defenses and the
attempt by viruses to overcome host defense during infec-
tion.
The range of interactions possible through miRNA-mRNA
cross-talk during host-virus interaction is complex [5].
Successful viruses effectively use the host machinery to
express viral proteins; while effective hosts limit viral
propagation by mobilizing innate and adaptive antiviral
defenses. miRNAs clearly have a central role in modulat-
ing gene expression during pathogen-host interaction.
There have been reports that predict candidate miRNAs of
viral origin (vmiRNAs) that would target host genes to
facilitate virus replication [6]. As well, there are predicted
target sites for human encoded miRNAs in HIV genes [7].
In a recent report Konstantinova et al. [8] constructed
HIV-1 which expresses a stable 300 bp long hairpin RNA
(lhRNA) targeted to Nef and LTR sequences and found
that this viral construction induce antiviral effects against
wild-type HIV-1 in trans, perhaps through a sequence-spe-
cific RNAi mechanism, although direct data supporting
that were not demonstrated. This finding is consistent
with the notion that mammalian cells are fully competent
for processing of miRNA, siRNA, or shRNA sequences
within the context of an HIV-1 genome.
Rapid progress in miRNA research is currently hampered
by lack of accuracy in predictions of the physiologically
relevant transcripts targeted by miRNAs. Indeed, although
computer based prediction programs are easily accessible,
empirical results suggest that many in silico predictions of
miRNA targeted genes will have to be experimentally val-
idated in biological assays. The complexity of the system
is in part due to the finding that one miRNA can have
binding sites in multiple targets and one transcript can be
attacked by many discrete miRNAs [9]. Computational
algorithms for miRNA prediction that rely heavily on
sequence conservation may prove to be inadequate for
viruses. A more useful strategy may incorporate embed-
ded secondary signals in either the RNA itself, or the struc-
ture of the resulting RNA-RNA or RNA-protein in the RISC
complex to carry out the analogue action required for
accurate miRNA targeting [10]. Examples are complexes
of RNA modifying enzymes which act at a site adjacent to
and determined by the position of the snoRNA:target
interaction [11] and the RISC complexes [12].
Viral miRNAs, unlike their vertebrate counterparts, do not
share a high level of homology, even within members of
the same family or with that of the host. RNA viruses as
compared to the DNA viruses, since their RNA genome is
more susceptible to attack by RNAi, are less likely to main-
tain RNAi-targeted sites. There is however an interesting
example [13] of accumulation of HCV RNA induced by
liver specific miR-122. This novel mechanism involving
the interaction of miR-122 and the 5'UTR of HCV RNA
may have evolved in parallel with the highly conserved
5'UTR secondary structure of HCV RNA essential for trans-
lational control of viral proteins. In another example [14],
mammalian microRNA, miR-32 has been shown to
restrict the accumulation of the retrovirus, primate foamy
virus type-1 (PFV-1, akin to human HIV). Cellular
miRNA, miR-32 efficiently inhibits the replication of PFV-
1 by hybridizing with the 3'UTR of viral mRNAs [15].
Remarkably, HIV-1 Tat has been shown to inhibit Dicer
activity, independently of its transcriptional function
[16,17]. Studies on the involvement of miRNAs in regula-
tion of innate immune response showed that miR-146a/b
may function as novel negative regulators that fine-tune
the immune response [18]. Furthermore, post-transcrip-
tional repression of gene expression mediated by miRNA
appears to be subject to regulation by physiological stress
in human cells [19].
These are exciting times for non-coding RNAs (ncRNAs)
that come not only in small forms. In the coming period,
one can expect to gain novel insights into the regulation
of mammalian gene expression by a better reading of the
language of ncRNAs.
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